Regional Gray Matter Volume Abnormalities in the At Risk Mental State
Stefan Borgwardt(Social Neuroscience Lab), Philip McGuire(Warneford Hospital), Marlon Pflüger(University Hospital of Basel), Paola Dazzan(King's College London), Marcus D’Souza(University Hospital of Basel), Ute Gschwandtner(University Hospital of Basel), Anita Riecher‐Rössler(University Hospital of Basel), Sven Haller(Ulsan College), Rolf‐Dieter Stieglitz(University Medical Center Freiburg), Evelyne Rechsteiner(University Hospital of Basel), Xavier Chitnis(King's College London), Margret Drewe(University Hospital of Basel), Ernst‐Wilhelm Radü(University Hospital of Basel), Jacqueline Aston(University Hospital of Basel)
Cited by 313
Related Papers
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
|The Lancet|2008|1.1k
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
|Molecular Psychiatry|2023|684
Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period
|The Lancet|2014|658
Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study
|The Lancet Psychiatry|2015|598
High-potency cannabis and the risk of psychosis
|The British Journal of Psychiatry|2009|577